Payment overview · 2025
General Payments
$431.13
20 reported records · 5 companies
Healthcare provider profile · identity verified
Catherine King, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · MESQUITE, NV · NPI 1225236862
Verified facts
What the public records show
CMS Open Payments records show Catherine King, APN received $431.13 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 69.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $300.15 | 69.6% | 14 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.72 | 10.8% | 3 | 2025 |
| Medline Industries LP | Unresolved — no canonical attribution shown | $43.83 | 10.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $26.46 | 6.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.97 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.13 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.56 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.72 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $9.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 961 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 639 | 167 |
| Lisinopril | Lisinopril | 629 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 507 | 150 |
| Losartan Potassium | Losartan Potassium | 475 | 139 |
| Metformin Hcl | Metformin Hcl | 402 | 127 |
| Omeprazole | Omeprazole | 345 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 80 |
| Simvastatin | Simvastatin | 267 | 79 |
| Gabapentin | Gabapentin | 248 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 67 |
| Potassium Chloride | Potassium Chloride | 224 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 58 |
| Furosemide | Furosemide | 193 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 61 |
| Trazodone Hcl | Trazodone Hcl | 172 | 60 |
| Allopurinol | Allopurinol | 147 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 43 |
| Alendronate Sodium | Alendronate Sodium | 135 | 40 |
| Ozempic | Semaglutide | 127 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 57 |
| Eliquis | Apixaban | 121 | 37 |
| Montelukast Sodium | Montelukast Sodium | 117 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 33 |
| Tramadol Hcl | Tramadol Hcl | 115 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 32 |
| Bupropion Xl | Bupropion Hcl | 108 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 33 |
| Sertraline Hcl | Sertraline Hcl | 107 | 29 |
| Mounjaro | Tirzepatide | 106 | 19 |
| Farxiga | Dapagliflozin Propanediol | 104 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 34 |
| Carvedilol | Carvedilol | 99 | 29 |
| Spironolactone | Spironolactone | 86 | 29 |
| Jardiance | Empagliflozin | 83 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 25 |
| Metformin Hcl Er | Metformin Hcl | 78 | 22 |
| Atenolol | Atenolol | 76 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 25 |
| Synthroid | Levothyroxine Sodium | 65 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 20 |
| Famotidine | Famotidine | 60 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 59 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 22 |
| Estradiol | Estradiol | 57 | 27 |
| Ondansetron Odt | Ondansetron | 55 | 23 |
| Prednisone | Prednisone | 55 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 19 |
| Lovastatin | Lovastatin | 51 | 14 |
| Alprazolam | Alprazolam | 49 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 17 |
| Warfarin Sodium | Warfarin Sodium | 49 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 13 |
| Celecoxib | Celecoxib | 44 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 19 |
| Trulicity | Dulaglutide | 43 | 12 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 14 |
| Glimepiride | Glimepiride | 40 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 14 |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | 11 |
| Acyclovir | Acyclovir | 33 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Fluconazole | Fluconazole | 23 | 15 |
| Nystatin | Nystatin | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | 11 |
| Meloxicam | Meloxicam | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Prolia | Denosumab | 15 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Euthyrox | Levothyroxine Sodium | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.13 · 20 records | Novo Nordisk Inc | BREZTRI, Dexcom G6 Transmitter, KRYSTEXXA, Ozempic, Rybelsus, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error